why choose us

First received: March 20, 2026

Clinical Trial: Clinico-pathological and Genomic Features of HER2-low Early Breast Cancer

Study Status: COMPLETED

Recruit Status: COMPLETED

Condition: HER2-zero, HER2-low and HER2-positive Tumors Distribution Across HR Expression Categories

Study Type: OBSERVATIONAL


Official Title: Clinico-pathological and Genomic Features of HER2-low Early Breast Cancer (eBC). Results of Retrospective Analysis of Seven Adjuvant Trials by the Hellenic Cooperative Oncology Group (HeCOG)

Brief Summary: Although breast cancer remains one of the most common and fatal cancer types among women worldwide, earlier diagnosis and improved therapeutic approaches have led to decreased mortality over last years. Indeed, the use of HER2-targeted drugs has improved clinical outcomes for patients with HER2 positive breast cancer, while, on the other hand, until recently, little progress has been made for HER2-negative (IHC score 0 and 1+) patients.However, it seems that among these HER2-negative breast cancers, substantial…

Read more